The success of molecular-targeted therapy depends on the identification of a landmark to select patients with more benefit from the therapy, such as activating mutation or gene amplification of EGFR in non-small cell lung cancer [33], and overexpression or gene amplification of HER2 in breast cancer [34]. This evidence concerns the gene EGFR and breast carcinoma.